Prime Medicine (PRME)
Develops Prime Editing therapies for liver, lung, and partnered cell-therapy programs.
Something off on this page? Send us feedback.
Builds gene-editing therapies around the Prime Editing platform, with internal work centered on Wilson Disease, AATD, and cystic fibrosis plus partnered ex vivo T-cell programs. Revenue has come from collaboration and license agreements, while commercialization depends on clinical testing, regulatory approval, and licensed platform rights.
Develops genetic medicines using Prime Editing, a platform designed to make defined DNA edits without double-stranded DNA breaks. The active pipeline is led by liver-directed in vivo programs for Wilson Disease and AATD, with cystic fibrosis work supported by the Cystic Fibrosis Foundation and ex vivo T-cell editing partnered with Bristol Myers Squibb.
Operates from Cambridge with no approved product sales, so the business surface is pipeline execution, collaboration revenue, and access to licensed Prime Editing rights from Broad Institute, MIT, and Harvard. Research is organized through internal programs and external partners rather than commercial franchises.
Execution now centers on moving Wilson Disease into clinical study, advancing AATD regulatory work, and keeping cystic fibrosis and T-cell programs funded through collaborations. AATD remains linked to Beam arbitration, and future product revenue depends on clinical testing and regulatory approval.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 25, 2026 | Chardan Capital | Reiterate | Rating: —Target: — | Target: $7 |
| Aug 18, 2026 | BMO Capital | Initiate | Rating: —Target: $19 | Target: $9 |
| Jun 29, 2026 | H.C. Wainwright | Upgrade | ||
| Jun 29, 2026 | New Street | Target | Target: — | Target: $8 |
| Jun 29, 2026 | HC Wainwright & Co. | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $95.1M · Total debt $112.5M · Total assets $249.0M · Shareholders' equity $39.8M
- Revenue
- $1.2M
- Operating income
- −$43.3M
- Net income
- −$42.1M
No dividends on record.
| Institutions | 59.31% | 107.58M shares | |
|---|---|---|---|
| 195 holders · as of Jun 30, 2026 | |||
| Insiders | 23.74% | 43.07M shares | |
| 7 holders · as of Aug 11, 2025 | |||
| Other | 16.95% | 30.73M shares | |
| remainder | |||
181.38M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
David R. LiuInsider10 percent owner | 11.16% | 20.24M | filed Jul 1, 2025 |
Robert Nelsen1Insiderdirector, 10 percent owner | 10.25% | 18.59M | filed Aug 11, 2025 |
Alphabet Inc.Institution | 9.13% | 16.56M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.29% | 9.60M | as of Jun 30, 2026 |
Ark Investment Management LLCInstitution | 4.60% | 8.35M | as of Jun 30, 2026 |
- Robert Nelsen's transaction reports restate only vehicles that traded; the 2025 ownership statement (18.59M) is used instead.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Beam Therapeutics
Base-editing rival in AATD and edited blood-cell therapies
- Intellia Therapeutics
Late-stage in vivo CRISPR leader for liver-delivered editing
- CRISPR Therapeutics
Commercial CRISPR platform spanning ex vivo and liver editing
- Editas Medicine
In vivo CRISPR peer focused on liver and HSC editing
- Wave Life Sciences
RNA-editing AATD rival with liver-directed WVE-006
- Caribou Biosciences
CRISPR-edited allogeneic CAR-T peer in hematologic cancers
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Prime Medicine | $3.40 | +6.58% | $576.2M | — | — | 141.5 | +3.5% |
| Beam Therapeutics | $26.09 | +3.29% | $2.60B | — | — | 16.7 | −94.2% |
| Intellia Therapeutics | $12.68 | +3.76% | $1.71B | — | — | 28.7 | −46.2% |
| CRISPR Therapeutics | $57.88 | −0.77% | $5.63B | — | — | 420.1 | +1,041.4% |
| Editas Medicine | $2.87 | +1.43% | $434.3M | — | — | 9.2 | +232.3% |
| Wave Life Sciences | $4.42 | +3.88% | $838.4M | — | — | 12.8 | −73.9% |
| Caribou Biosciences | $1.33 | +2.31% | $128.9M | — | — | 12.8 | −43.8% |
| Median | — | — | 14.8 | −45.0% |